RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
-8.24%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.44B
AUM Growth
+$3.44B
(-14%)
Cap. Flow
+$132M
Cap. Flow
% of AUM
3.85%
Top 10 Holdings %
Top 10 Hldgs %
35%
Holding
142
New
7
Increased
68
Reduced
12
Closed
10
Top Buys
| 1 |
Align Technology
ALGN
|
$32.7M |
| 2 |
Humana
HUM
|
$27M |
| 3 |
Health Care Select Sector SPDR Fund
XLV
|
$25.6M |
| 4 |
Penumbra
PEN
|
$24.5M |
| 5 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$20.5M |
Top Sells
| 1 |
HCA Healthcare
HCA
|
$94M |
| 2 |
Encompass Health
EHC
|
$35.7M |
| 3 |
iRhythm Technologies
IRTC
|
$17.9M |
| 4 |
XENT
Intersect ENT, Inc
XENT
|
$15.4M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
$14.7M |
Sector Composition
| 1 | Healthcare | 96.7% |
| 2 | Consumer Staples | 0.96% |
| 3 | Industrials | 0.47% |
| 4 | Financials | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Legend Biotech
LEGN
$6.64B
| $19.6M | 0.57% |
355,567
-55,617
| -14% | -$3.06M |
|
|
CINC
52
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $19.2M | 0.56% |
1,021,159
-10,000
| -1% | -$188K |
|
53
Mersana Therapeutics
MRSN
$34.8M
| $18.8M | 0.55% |
4,075,958
+320,138
| +9% | +$1.48M |
|
54
Amylyx Pharmaceuticals
AMLX
$877M
| $18.8M | 0.55% |
974,107
-24,200
| -2% | -$466K |
|
|
OLK
55
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $18.7M | 0.54% |
1,231,800
+245,800
| +25% | +$3.74M |
|
56
Prothena Corp
PRTA
$452M
| $18.4M | 0.54% |
678,462
+14,932
| +2% | +$405K |
|
|
RXDX
57
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $18.2M | 0.53% |
644,507
+20,200
| +3% | +$570K |
|
|
ACCD
58
DELISTED
Accolade, Inc. Common Stock
ACCD
| $16.3M | 0.47% |
2,200,000
+695,000
| +46% | +$5.14M |
|
59
Cytokinetics
CYTK
$5.98B
| $15.7M | 0.46% |
+400,000
| New | +$15.7M |
|
60
BioCryst Pharmaceuticals
BCRX
$1.74B
| $15.5M | 0.45% |
+1,461,091
| New | +$15.5M |
|
61
Kymera Therapeutics
KYMR
$3.1B
| $15.3M | 0.44% |
775,879
+20,004
| +3% | +$394K |
|
62
Warby Parker
WRBY
$3.08B
| $14.3M | 0.42% |
1,273,500
+235,000
| +23% | +$2.65M |
|
63
Aura Biosciences
AURA
$394M
| $14.3M | 0.42% |
1,008,814
+700
| +0.1% | +$9.92K |
|
64
Compass Therapeutics
CMPX
$466M
| $14.1M | 0.41% |
5,328,088
| – | – |
|
65
Health Catalyst
HCAT
$228M
| $13.7M | 0.4% |
945,400
+31,900
| +3% | +$462K |
|
66
Biomea Fusion
BMEA
$114M
| $13M | 0.38% |
1,085,740
-79,842
| -7% | -$956K |
|
67
Collegium Pharmaceutical
COLL
$1.25B
| $12.8M | 0.37% |
725,000
| – | – |
|
|
INZY
68
DELISTED
Inozyme Pharma
INZY
| $12.6M | 0.37% |
2,640,056
+1,446,861
| +121% | +$6.9M |
|
69
NovoCure
NVCR
$1.35B
| $12.2M | 0.35% |
175,000
| – | – |
|
70
Arvinas
ARVN
$580M
| $11.8M | 0.34% |
280,100
-177,500
| -39% | -$7.47M |
|
71
Azenta
AZTA
$1.35B
| $11.7M | 0.34% |
+162,000
| New | +$11.7M |
|
72
AnaptysBio
ANAB
$630M
| $11.6M | 0.34% |
572,300
+9,000
| +2% | +$183K |
|
73
Lifestance Health
LFST
$2.14B
| $11.1M | 0.32% |
2,000,000
| – | – |
|
|
EPZM
74
DELISTED
Epizyme, Inc
EPZM
| $11M | 0.32% |
7,485,543
+217,847
| +3% | +$320K |
|
75
Amicus Therapeutics
FOLD
$2.42B
| $10.9M | 0.32% |
1,012,506
| – | – |
|